Check out our full report below:
Regulatory
The US FDA Accepts GSK’s BLA of Meningococcal ABCWY Vaccine for Invasive Meningococcal Disease (IMD)
Read More: GSK
NovelMed’s NM5072 Receives the US FDA’s Orphan Drug Designation to Treat Paroxysmal Nocturnal Hemoglobinuria (PNH)
Read More: NovelMed
Sentynl Therapeutics’ Nulibry (fosdenopterin) Gains the MHRA’s Approval to Treat Molybdenum Cofactor Deficiency (MoCD) Type A
Read More: Sentynl Therapeutics
Takeda’s Entyvio Receives the US FDA’s Approval for Subcutaneous Administration to Treat Moderately to Severely Active Crohn’s Disease (CD)
Read More: Takeda
Nxera Pharma Collaborates with Handok to Commercialize Pivlaz in South Korea
Read More: Nxera Pharma
Medincell Collaborates with AbbVie for the Development of Therapies Across Various Indications
Read More: Medincell and AbbVie
IGM Biosciences Revises its Collaboration with Sanofi
Read More: IGM Biosciences
Essential Pharma Acquires Reminyl (galantamine hydrobromide) Oral Capsules from Janssen
Read More: Essential Pharma & Reminyl
TELA Bio Launches OviTex IHR to Repair Inguinal Hernia Across the US
Read More: TELA Bio
Shinobi Therapeutics Teams Up with Panasonic to Develop Affordable and Efficient iPS Cell Therapy Manufacturing Technology
Read More: Shinobi Therapeutics
AbbVie Reports Data from the P-III Trial of Atogepant as a Preventive Treatment of Migraine
Read More: AbbVie
Roche Reports Data from the P-III Clinical Evaluation of Columvi to Treat R/R Diffuse Large B-cell Lymphoma
Read More: Roche
MaaT Pharma to Highlight Data from the Early Access Program of MaaT013 to Treat Acute Graft-Versus-Host Disease (aGvHD) at EBMT 2024
Read More: MaaT Pharma
Novartis Reports Data from the P-III Study of Fabhalta (iptacopan) for the Treatment of IgA Nephropathy (IgAN)
Read More: Novartis
ORIC Pharmaceuticals Doses First Patients Across Expansion Arms in the P-Ib Study of ORIC-114 for the Treatment of Mutated NSCLC
Read More: ORIC Pharmaceuticals
Corcept Concludes Patient Recruitment in the P-II Study of Dazucorilant for Amyotrophic Lateral Sclerosis (ALS)
Read More: Corcept
AstraZeneca Reports Results from the P-III (TOPAZ-1) Study of Imfinzi for Treating Advanced Biliary Tract Cancer
Read More: AstraZeneca
Sanofi to Highlight New Data from the P-II Study of Frexalimab for the Treatment of Multiple Sclerosis at AAN 2024
Read More: Sanofi
GSK to Feature Results from the P-III (ZOSTER-049) Study of Shingrix for Protection Against Shingles at ESCMID Global 2024
Read More: GSK
Roche to Highlight the P-III (OCARINA II) Trial Results of Ocrevus for Treating Progressive and Relapsing Multiple Sclerosis at AAN 2024
Read More: Roche
GSK to Highlight Results from the P-III (EAGLE-1) Study of Gepotidacin for Treating Uncomplicated Urogenital Gonorrhoea (GC) at ESCMID 2024
Read More: GSK
Lilly Reports the P-III (SURMOUNT-OSA) Study Data of Tirzepatide in Patients with Obstructive Sleep Apnea (OSA) and Obesity
Read More: Eli Lilly
Artiva Biotherapeutics Doses First Patient with AlloNK in the P-I Study for Treating Lupus Nephritis
Read More: Artiva
Cerevel Therapeutics Reports Results from P-III Adjunctive Study Evaluating Tavapadon for the Treatment of Advanced Parkinson’s Disease
Read More: Cerevel
Oncternal Therapeutics Reports First Patient Dosing in Fourth Cohort of P-I/II Study of ONCT-534 for the Treatment of R/R mCRPC
Read more: Oncternal Therapeutics
Ventus Therapeutics Reports Results from the P-I Study of VENT-02 in Healthy Volunteers
Read more: Ventus Therapeutics
Teva and Alvotech’s Selarsdi (Biosimilar, Stelara) Receives the US FDA’s Approval
Read More: Teva Pharmaceuticals
Seismic Therapeutic Highlights Preclinical Data of S-1117 for the Treatment of Autoimmune Disorders at AAN 2024
Read More: Seismic Therapeutic
